A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Public ClinicalTrials.gov record NCT06393712. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Study identification
- NCT ID
- NCT06393712
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2024
- Primary completion
- Aug 8, 2027
- Completion
- Dec 13, 2029
- Last update posted
- Sep 2, 2026
2024 – 2029
United States locations
- U.S. sites
- 26
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Los Angeles | California | 90095 | — |
| Clinical Trial Site | Palo Alto | California | 94304 | — |
| Clinical Trial Site | Sacramento | California | 95816 | — |
| Clinical Trial Site | San Francisco | California | 94114 | — |
| Clinical Trial Site | Gainesville | Florida | 32608 | — |
| Clinical Trial Site | Jacksonville | Florida | 32224 | — |
| Clinical Trial Site | Maitland | Florida | 32751 | — |
| Clinical Trial Site | Naples | Florida | 34105 | — |
| Clinical Trial Site | Chicago | Illinois | 60612 | — |
| Clinical Trial Site | Lexington | Kentucky | 40504 | — |
| Clinical Trial Site | New Orleans | Louisiana | 70121 | — |
| Clinical Trial Site | Boston | Massachusetts | 02114 | — |
| Clinical Trial Site | Rochester | Minnesota | 55905 | — |
| Clinical Trial Site | St Louis | Missouri | 63110 | — |
| Clinical Trial Site | New York | New York | 10029 | — |
| Clinical Trial Site | New York | New York | 10032 | — |
| Clinical Trial Site | New York | New York | 10065 | — |
| Clinical Trial Site | Durham | North Carolina | 27705 | — |
| Clinical Trial Site | Cleveland | Ohio | 44195 | — |
| Clinical Trial Site | Abington | Pennsylvania | 19001 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Trial Site | Dallas | Texas | 75243 | — |
| Clinical Trial Site | Dallas | Texas | 75390 | — |
| Clinical Trial Site | Houston | Texas | 77030 | — |
| Clinical Trial Site | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06393712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06393712 live on ClinicalTrials.gov.